title: Infusion-related hypersensitivity reactions during natalizumab treatment.
authors.affiliation: Multiple Sclerosis Center at Texas Neurology, Dallas, TX 75214, USA. JTPhillips@TexasNeurology.com
authors.forename: J T
authors.initials: JT
authors.lastname: Phillips
authors.forename: P W
authors.initials: PW
authors.lastname: O'Connor
authors.forename: E
authors.initials: E
authors.lastname: Havrdova
authors.forename: M
authors.initials: M
authors.lastname: Hutchinson
authors.forename: L
authors.initials: L
authors.lastname: Kappos
authors.forename: D H
authors.initials: DH
authors.lastname: Miller
authors.forename: C H
authors.initials: CH
authors.lastname: Polman
authors.forename: F D
authors.initials: FD
authors.lastname: Lublin
authors.forename: G
authors.initials: G
authors.lastname: Giovannoni
authors.forename: A
authors.initials: A
authors.lastname: Wajgt
authors.forename: F
authors.initials: F
authors.lastname: Lynn
authors.forename: M A
authors.initials: MA
authors.lastname: Panzara
authors.forename: A W
authors.initials: AW
authors.lastname: Sandrock
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D002395:Catecholamines / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000276:immunology / Q000503:physiopathology*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D008991:Monitoring, Physiologic / Q000592:standards; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002395:Catecholamines; D006634:Histamine H1 Antagonists; D000069442:Natalizumab